These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31453215)

  • 1. Protocol for evaluation of neurotrophic strategies in Parkinson's disease-related dopaminergic and sympathetic neurons
    Hegarty SV; Sullivan AM; O'Keeffe GW
    J Biol Methods; 2016; 3(3):e50. PubMed ID: 31453215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin- and α-synuclein-induced degeneration in cellular models of Parkinson's disease.
    Mazzocchi M; Goulding SR; Wyatt SL; Collins LM; Sullivan AM; O'Keeffe GW
    Mol Cell Neurosci; 2021 Sep; 115():103642. PubMed ID: 34119632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Small Molecule Activator of p300/CBP Histone Acetyltransferase Promotes Survival and Neurite Growth in a Cellular Model of Parkinson's Disease.
    Hegarty SV; O'Leary E; Solger F; Stanicka J; Sullivan AM; O'Keeffe GW
    Neurotox Res; 2016 Oct; 30(3):510-20. PubMed ID: 27256286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BMP2 and GDF5 induce neuronal differentiation through a Smad dependant pathway in a model of human midbrain dopaminergic neurons.
    Hegarty SV; Sullivan AM; O'Keeffe GW
    Mol Cell Neurosci; 2013 Sep; 56():263-71. PubMed ID: 23831389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of
    Hegarty SV; Sullivan AM; O'Keeffe GW
    Neuronal Signal; 2018 Mar; 2(1):NS20170181. PubMed ID: 32714583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene co-expression analysis of the human substantia nigra identifies BMP2 as a neurotrophic factor that can promote neurite growth in cells overexpressing wild-type or A53T α-synuclein.
    Goulding SR; Sullivan AM; O'Keeffe GW; Collins LM
    Parkinsonism Relat Disord; 2019 Jul; 64():194-201. PubMed ID: 31000327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson's disease.
    Goulding SR; Sullivan AM; O'Keeffe GW; Collins LM
    Neural Regen Res; 2020 Aug; 15(8):1432-1436. PubMed ID: 31997802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GDNF family ligands: a potential future for Parkinson's disease therapy.
    Mickiewicz AL; Kordower JH
    CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):703-11. PubMed ID: 21838676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.
    Goulding SR; Anantha J; Collins LM; Sullivan AM; O'Keeffe GW
    Neural Regen Res; 2022 Jan; 17(1):38-44. PubMed ID: 34100424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exercise-Induced Neuroprotection and Recovery of Motor Function in Animal Models of Parkinson's Disease.
    Palasz E; Niewiadomski W; Gasiorowska A; Wysocka A; Stepniewska A; Niewiadomska G
    Front Neurol; 2019; 10():1143. PubMed ID: 31736859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease.
    Voutilainen MH; Arumäe U; Airavaara M; Saarma M
    FEBS Lett; 2015 Dec; 589(24 Pt A):3739-48. PubMed ID: 26450777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting bone morphogenetic protein signalling in midbrain dopaminergic neurons as a therapeutic approach in Parkinson's disease.
    O'Keeffe GW; Hegarty SV; Sullivan AM
    Neuronal Signal; 2017 Apr; 1(2):NS20170027. PubMed ID: 32714578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease.
    Hegarty SV; O'Keeffe GW; Sullivan AM
    Neural Regen Res; 2014 Oct; 9(19):1708-11. PubMed ID: 25422631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral vector delivery of neurotrophic factors for Parkinson's disease therapy.
    Kelly MJ; O'Keeffe GW; Sullivan AM
    Expert Rev Mol Med; 2015 May; 17():e8. PubMed ID: 25997719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of growth factors for the treatment of Parkinson's disease.
    Yasuda T; Mochizuki H
    Expert Rev Neurother; 2010 Jun; 10(6):915-24. PubMed ID: 20518608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
    Sano H; Murata M; Nambu A
    J Neurochem; 2015 Jul; 134(2):371-81. PubMed ID: 25857446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats.
    Pang Y; Lin S; Wright C; Shen J; Carter K; Bhatt A; Fan LW
    Neuroscience; 2016 Mar; 318():157-65. PubMed ID: 26777890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Neurotrophic Factors in Parkinson's Disease.
    Tome D; Fonseca CP; Campos FL; Baltazar G
    Curr Pharm Des; 2017; 23(5):809-838. PubMed ID: 27928963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease.
    Levivier M; Przedborski S; Bencsics C; Kang UJ
    J Neurosci; 1995 Dec; 15(12):7810-20. PubMed ID: 8613721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.